Human Immunology News Volume 1.00 | Mar 12 2013

    0
    53

    Human Immunology News 1.00 March 12, 2013

    HIN_EloquaHeader

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Human Immunology News on Twitter

    TOP STORY
    The Clinical Impact of Humoral Immunity in Pediatric Renal Transplantation
    Investigators studied the evolution of humoral immunity in low-risk pediatric patients during the first two years after renal transplantation. Using data from 130 pediatric renal transplant patients randomized to steroid-free or steroid-based immunosuppression, they correlated the presence of serum anti-HLA antibodies to donor HLA antigens and serum MHC class 1-related chain A antibody with both clinical outcomes and histology identified on protocol biopsies at 0, 6, 12, and 24 months. [JAMA-J Am Med Assoc]
    Abstract | Press Release

    View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)

    PUBLICATIONS (Ranked by impact factor of the journal)

    Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12- and IL-15-Responsive IFN-γ-Producing Cells
    Scientists characterized a human innate lymphoid cell 1 (ILC1) subset that produced interferon-γ (IFN-γ) in response to interleukin (IL)-12 and IL-15 and had a unique integrin profile, intraepithelial location, hallmarks of TGF-β imprinting, and a memory-activated phenotype. [Immunity] Abstract

    Cetuximab-Activated Natural Killer (NK) and Dendritic Cells (DC) Collaborate to Trigger Tumor Antigen-Specific T Cell Immunity in Head and Neck Cancer Patients
    Flow cytometry was performed to quantify EGFR-specific T cells in cetuximab-treated head and neck cancer (HNC) patients. The effect of cetuximab on NK cell, DC, and T cell activation was measured using IFN-γ release assays and flow cytometry. FcRγIIIa polymorphism did not predict clinical outcome in cetuximab-treated HNC patients, however elevated circulating EGFR853-861-specific CD8+ T cells were found in cetuximab-treated HNC patients. [Clin Cancer Res] Abstract

    Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma with Bispecific Antibodies In Vitro and in Patients
    Scientists tested for functional natural killer (NK) cell defects in Hodgkin lymphoma (HL) and suggest an improvement of NK function by therapeutic means. They demonstrated that peripheral NK cells from patients with HL fail to eliminate HL cell lines in ex vivo killing assays. Impaired NK cell function correlated with elevated serum levels of soluble ligands for NK cell receptors NKp30 and NKG2D, factors known to constrict NK cell function. [Mol Ther] Full Article

    Potential Contribution of a Novel Tax Epitope-Specific CD4+ T Cells to Graft-versus-Tax Effect in Adult T Cell Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation
    Scientists showed that Tax-specific CD4+ as well as CD8+ T cell responses were induced in some adult T cell leukemia/lymphoma patients following allogeneic hematopoietic stem cell transplantation. [J Immunol] Abstract

    The Different Immunoregulatory Functions on Dendritic Cells between Mesenchymal Stem Cells Derived from Bone Marrow of Patients with Low-Risk or High-Risk Myelodysplastic Syndromes
    Researchers confirm that myelodysplastic syndrome-mesenchymal stem cells (MDS-MSC) mediate a potent inhibition of dendritic cells (DCs) differentiation. Additionally, MDS-MSC greatly alter DCs functions, including endocytosis, IL-12 secretion, their ability to inhibit T cell proliferation. Moreover, their results show that there are major differences in DC development and function between low-risk and high-risk MDS-MSC. [PLoS One] Full Article

    The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes
    The authors characterized the in vitro immuno-stimulatory activities of a novel benzazepine toll-like receptor 8 (TLR8) agonist, VTX-294, in comparison to imidazoquinolines that activate TLR8 (R-848; (TLR7/8) CL075; (TLR8/7)), with respect to activation of human newborn and adult leukocytes. [PLoS One]
    Full Article | Press Release

    Characterization of Regulatory T Cells in Decidua of Miscarriage Cases with Abnormal or Normal Fetal Chromosomal Content
    Decreased regulatory T (Treg) cells have been reported in cases of recurrent pregnancy loss. To understand the role of Treg cells in human pregnancy, researchers studied the frequency, localization and characterization of Treg cells in the decidua. The frequency of Foxp3+ cells among CD3+CD8 cells at the decidua basalis in cases of miscarriage with a normal embryo karyotype was significantly lower than in normally progressing pregnancies. However, those frequencies in miscarriage with an abnormal embryo karyotype were similar to normally progressing pregnancies. [J Reprod Immunol] Abstract | Full Article

    Polyinosinic-Cytidylic Acid as an Adjuvant on Natural Killer- and Dendritic Cell-Mediated Antitumor Activities
    Scientists examined the ability of E7(44-62) with polyinosinic-cytidylic acid to induce toll-like receptor 3 expression, tumor necrosis factor-alpha and interferon-gamma mRNA expression, and tumor cell-killing activity in human natural killer cells as well as its ability to induce CD11c and CD86 expression and proliferation in human dendritic cells. [Tumour Biol] Abstract

    Don’t forget to subscribe to our sister publications: Immunology of Infectious Disease News and Immune Regulation News!

    Learn more about the new smartphone app for human blood cell frequencies

    REVIEWS
    B Cell Localization: Regulation by EBI2 and Its Oxysterol Ligand
    The authors review the current findings that have delineated the function of EpsteinBarr virus-induced molecule 2 (EBI2) and its ligand and discuss how they collaborate with conventional lymphoid chemokine systems to position B cells optimally during immune responses. [Trends Immunol] Abstract

    SCIENCE NEWS
    KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
    KaloBios Pharmaceuticals, Inc. presented data from its Phase I/II study in persistent asthma for KB002. The findings demonstrated preliminary safety, tolerability, and signs of activity of anti-GM-CSF antibodies in asthma and support continued development of the company’s Humaneered® KB003 anti-GM-CSF monoclonal antibody in severe asthma. [Press release from KaloBios Pharmaceuticals, Inc. discussing research presented at the American Academy of Allergy, Asthma & Immunology Annual (AAAI) Meeting, San Antonio] Press Release

    Sangamo Presents New Clinical Data Demonstrating Persistent Immune System Improvements after Treatment with ZFN Therapeutic® SB-728-T
    Sangamo BioSciences, Inc. announced new data from its program to develop a ‘functional cure’ for HIV/AIDS in two presentations. The first presentation described data from the SB-728-T Phase I study demonstrating that SB-728-T treatment of HIV-infected subjects leads to durable reconstitution of the immune system driven by increases in total CD4+ central memory T-cells (TCM) and CCR5-protected TCM. Data were also presented from a research stage study. [Press release from Sangamo BioSciences, Inc. discussing research presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta] Press Release

    INDUSTRY NEWS

    Takeda and Resolve Therapeutics Enter Autoimmune Partnership

    Takeda Pharmaceutical Company Ltd. and Resolve Therapeutics, LLC jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus and other autoimmune diseases. [Takeda Pharmaceutical Company Limited] Press Release


    BioLineRx’s EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company’s Main Therapeutic Pipeline as BL-9010

    BioLineRx announced that following promising pre-clinical data, EDP-14, for the treatment of severe and persistent asthma, has been added to the Company’s main therapeutic pipeline. [BioLineRx] Press Release

    Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
    Advanced Cell Diagnostics, Inc. (ACD) announced that they have entered into an agreement with The Johns Hopkins University on behalf of its Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins to use ACD’s proprietary RNAscope® technology platform to validate novel biomarkers and drug targets for cancer immunotherapy. [Advanced Cell Diagnostics, Inc.] Press Release

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW 26th Annual Canadian Society for Immunology (CSI) Conference
    April 5-8, 2013
    Whistler, Canada

    NEW 11th Cancer Immunotherapy (CIMT) Annual Meeting
    May 14-16, 2013
    Mainz, Germany

    Visit our events page to see a complete list of events in the human immunology community.

    JOB OPPORTUNITIES

    Faculty Position – Human Immunology (Translational Health Science and Technology Institute)

    Faculty Positions – Human and Translational Immunology (Yale University)

    Assistant Professor – Cellular Mechanisms of Innate Immune Response (La Jolla Institute for Allergy & Immunology)

    Head of Immunology – Autoimmune Diseases and Inflammation (1881 EMD Serono, Inc.)

    Postdoctoral Position – Mechanisms of Autoimmune Diseases (University of Florida)

    Postdoctoral Position – Immunology (Stanford University)

    Research Fellow – Readership in Immunology (University of Edinburgh)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Human Immunology News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

     

    Learn more about Human Immunology News: Archives | Events | Contact Us